27 August,
2016. Manchester, UK. Prous Institute for
Biomedical Research is to present the 2016 Prous Institute – Overton &Meyer Award to Professor Jan Steyaert, at the XXIV International Symposium onMedicinal Chemistry organized by the European Federation of Medicinal Chemistry
(EFMC).
The award, conferred every two
years, recognizes outstanding contributions to the development of new
technologies in the field of medicinal chemistry and acknowledges the awardee’s
contribution to the discovery and development of innovative technologies that
advance the field.
Prof Steyaert has pioneered
the use of nanobodies for chaperone-assisted X-ray crystallography aiming at
the highest hanging fruits of structural biology including membrane proteins,
amyloidogenic proteins, and multiprotein complexes. Recent work focuses on
exploiting the conformational complexity of therapeutic targets for nanobody-enabled
drug discovery.
Prof Steyaert is currently
Director of the Structural Biology Research Centre at Vrije Universiteit
Brussels (VUB) and Deputy-Director and group leader of the Structural Biology Research Center of the
Vlaams Instituut voor Biotechnologie (VIB).
The award will be presented
during the XXIV International Symposium on Medicinal Chemistry
(EFMC-ISMC 2016), to be held
on August 28 – September 1, 2016 in Manchester, United Kingdom.
About Prous Institute for Biomedical Research
Prous Institute for Biomedical Research is a research
company comprised of two business units: drug discovery and in silico
technologies. Prous Institute’s drug discovery and research unit is committed
to discovering novel therapies through the application of its proprietary drug
discovery platform, Symmetry.
Prous Institute’s in silico technologies
unit focuses on the research, development and commercialization of
chemoinformatics and toxicity prediction tools for drug discovery and safety
screening.